

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-16. (Canceled)

17. (Previously amended) The method of claim 27, wherein expression of said RNA in a tissue of said mammal elicits said tumor antigen-specific immune response in said mammal.

18-23. (Canceled).

24. (Previously amended) The method of claim 27, wherein said total RNA is isolated from an autologous tumor sample.

25. (Previously amended) A method to elicit a tumor antigen-specific immune response and a systemic, non-specific immune response in a mammal that has cancer, comprising administering to the mammal a therapeutic composition by a route of administration selected from the group consisting of intravenous and intraperitoneal administration, said therapeutic composition comprising:

(a) a liposome delivery vehicle; and,

(b) total RNA isolated from a tumor sample, said RNA encoding tumor antigens, wherein said total RNA is isolated from a plurality of allogeneic tumor samples of the same histological tumor type.

26. (Previously amended) The method of claim 25, wherein said cancer is selected from the group consisting of melanomas, squamous cell carcinoma, breast cancers, head and neck carcinomas, thyroid carcinomas, soft tissue sarcomas, bone sarcomas, testicular cancers, prostatic cancers, ovarian cancers, bladder cancers, skin cancers, brain cancers, angiosarcomas, hemangiosarcomas, mast cell tumors, primary hepatic cancers, lung cancers,

pancreatic cancers, gastrointestinal cancers, renal cell carcinomas, hematopoietic neoplasias, and metastatic cancers thereof.

27. (Previously amended) A method to elicit a tumor antigen-specific immune response and a systemic, non-specific immune response in a mammal that has cancer, comprising administering to the mammal a therapeutic composition by a route of administration selected from the group consisting of intravenous and intraperitoneal administration, said therapeutic composition comprising:

- (a) a liposome delivery vehicle; and,
- (b) total RNA isolated from a tumor sample, said RNA encoding tumor antigens, wherein said cancer is selected from the group consisting of a primary lung cancer and a pulmonary metastatic cancer.

28. (Previously amended) The method of claim 25, wherein said tumor antigen is from a cancer selected from the group consisting of melanomas, squamous cell carcinoma, breast cancers, head and neck carcinomas, thyroid carcinomas, soft tissue sarcomas, bone sarcomas, testicular cancers, prostatic cancers, ovarian cancers, bladder cancers, skin cancers, brain cancers, angiosarcomas, hemangiosarcomas, mast cell tumors, primary hepatic cancers, lung cancers, pancreatic cancers, gastrointestinal cancers, renal cell carcinomas, hematopoietic neoplasias and metastatic cancers thereof.

29. (Previously amended) The method of claim 27, wherein said tumor antigen is selected from the group consisting of tumor antigens having epitopes that are recognized by T cells, tumor antigens having epitopes that are recognized by B cells, tumor antigens that are exclusively expressed by tumor cells; and tumor antigens that are expressed by tumor cells and by non-tumor cells.

30. (Previously amended) The method of claim 27, wherein said administering produces a result selected from the group consisting of alleviation of said cancer, reduction of size of a tumor associated with said cancer, and stimulation of effector cell immunity against said cancer.

31. (Previously amended) The method of claim 27, wherein said administration of said composition by an intravenous route inhibits an increase in size of said pulmonary metastatic cancer in said mammal.

32-52. (Canceled)

53. (Withdrawn) The method of claim 27, wherein said RNA is enriched for poly-A RNA prior to said administration to said mammal.

54-67. (canceled)

68. (New) The method of claim 25, wherein said liposome delivery vehicle comprises lipids selected from the group consisting of multilamellar vesicle lipids and extruded lipids.

69. (New) The method of claim 25, wherein said liposome delivery vehicle comprises multilamellar vesicle lipids.

70. (New) The method of claim 25, wherein said liposome delivery vehicle comprises cationic liposomes.

71. (New) The method of claim 25, wherein said liposome delivery vehicle comprises pairs of lipids selected from the group consisting of DOTMA and cholesterol, DOTAP and cholesterol; DOTIM and cholesterol; and DDAB and cholesterol.

72. (New) The method of claim 25, wherein said liposome delivery vehicle comprises DOTAP and cholesterol.

73. (New) The method of claim 25, wherein said mammal is an human.

74. (New) The method of claim 25, further comprising a pharmaceutically acceptable excipient.